Detalhe da pesquisa
1.
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
Eur Respir J
; 57(6)2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33243847
2.
Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis.
Emerg Infect Dis
; 26(3)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31922953
3.
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis.
Eur Respir J
; 55(3)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31862767
4.
Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.
PLoS Med
; 15(7): e1002595, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29969463
5.
The impact of digital health technologies on tuberculosis treatment: a systematic review.
Eur Respir J
; 51(1)2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29326332
6.
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
Eur Respir J
; 49(3)2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28331043
7.
Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
Eur Respir J
; 50(1)2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28751411
8.
Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis.
Bull World Health Organ
; 95(8): 584-593, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28804170
9.
Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.
BMC Med
; 14(1): 187, 2016 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-27855693
10.
Digital health for the End TB Strategy: developing priority products and making them work.
Eur Respir J
; 48(1): 29-45, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27230443
11.
Towards cash transfer interventions for tuberculosis prevention, care and control: key operational challenges and research priorities.
BMC Infect Dis
; 16: 307, 2016 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27329161
12.
Multidrug-resistant tuberculosis around the world: what progress has been made?
Eur Respir J
; 45(1): 150-60, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25261327
13.
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
Eur Respir J
; 46(6): 1563-76, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26405286
14.
Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.
N Engl J Med
; 375(11): 1081-9, 2016 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27626523
15.
Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review.
Eur Respir J
; 43(6): 1763-75, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24525439
16.
The Role of Novel Approaches and New Findings in the Pharmacology of Tuberculosis Medicines in Improving Treatment Outcomes.
Clin Infect Dis
; 67(suppl_3): S365-S367, 2018 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30496462
17.
Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?
Eur Respir J
; 51(3)2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567722
18.
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
Eur Respir J
; 51(3)2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567719
19.
Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis.
Bull World Health Organ
; 96(10): 667-667A, 2018 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30455511
20.
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.
J Infect Dis
; 205 Suppl 2: S241-9, 2012 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22448022